MedTrace Logo

Interest of the Donor-specific Antibodies After Liver Transplantation

NCT03238443 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2021-03-25

No results posted yet for this study

Summary

The study is a prospective observational mono center study

Primary objective :

Study the anti-HLA antibodies frequency preformed before liver transplantation and the kinetic of appearance of DSA and de novo complement-binding anti-HLA antibodies after liver transplantation.

Secondary objective :

* Risk factor of de novo DSA appearance (Immunosuppressive therapy, liver aetiology)
* Impact of DSA on:

* Graft and patients survivals
* Onset of allograft rejection (acute, late-onset, chronic)
* Unexplained liver graft dysfunction
* Unexplained liver enzymes abnormalities
* Liver fibrosis development (liver stiffness study using fibroscan©)

Conditions

  • Liver Transplant

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Sébastien Dharancy, MD, PhD · University Hospital, Lille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-16
Primary Completion
2019-07-13
Completion
2019-07-13

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03238443 on ClinicalTrials.gov